GlassScriptPhysician profile
Kwan T Tan
NPI 1013099746
$16,472.27
in general payments reported to CMS, 2019-2025
44 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $1,197 · 2021: $2,818 · 2022: $1,960 · 2023: $2,526 · 2024: $3,881 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,765 · Travel and Lodging: $5.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,764.55 |
| Travel and Lodging | $5.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,422.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,710.02 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Novo Nordisk INC | $1,446.86 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,269.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,128.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,036.20 | 2019-2024 | Xarelto, Spravato |
| Abbvie INC. | $1,016.70 | 2021-2025 | Vraylar, Qulipta, Lo Loestrin Fe |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.60 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $753.38 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $568.52 | 2020-2025 | Epclusa, Vemlidy |
| Merck Sharp & Dohme LLC | $504.03 | 2020-2024 | Verquvo, Belsomra, Gardasil 9 |
| Pfizer INC. | $450.84 | 2019-2025 | |
| Abbott Laboratories | $340.38 | 2019-2024 | Freestyle Libre 3 |
| Radius Health, INC. | $259.98 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $243.64 | 2021-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $227.71 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $183.59 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $182.03 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.03 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $163.78 | 2024 | Voquezna |
| Exact Sciences Corporation | $160.73 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $158.73 | 2024-2025 | Rexulti |
| Allergan, INC. | $151.79 | 2019-2021 | |
| Medtronic USA, INC. | $144.13 | 2019 | |
| Dexcom, INC. | $142.12 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $118.86 | 2022 | |
| Horizon Therapeutics Plc | $117.41 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $84.83 | 2019-2023 | Dupixent |
| Sanofi-Aventis U.S. LLC | $79.21 | 2019-2022 | |
| Cranial Technologies, INC | $49.55 | 2019-2025 | Doc Band |
| Genzyme Corporation | $44.74 | 2022-2023 | |
| Sanofi Pasteur INC. | $38.45 | 2023-2024 | |
| Astellas Pharma US INC | $29.40 | 2020-2023 | Myrbetriq |
| Abiomed | $28.15 | 2025 | |
| Alk-Abello, INC | $27.51 | 2023 | Ragwitek, Odactra, Grastek |
| Lexicon Pharmaceuticals, INC. | $18.65 | 2024 | Inpefa |
| Xeris Pharmaceuticals, INC. | $16.62 | 2024 | Keveyis |
| Almatica Pharma LLC | $16.45 | 2021 | |
| Seqirus USA INC | $16.42 | 2025 | Flucelvax, Fluad |
| Hikma Pharmaceuticals USA | $16.23 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.23 | 2021 | |
| Eisai INC. | $16.14 | 2020 | |
| Aimmune Therapeutics, INC. | $15.30 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwan Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.